Press Releases

Disclaimer: Prior to June 2019, Caladrius Biosciences’ treatment for coronary microvascular dysfunction was referred to as CLBS14-CMD. To avoid confusion, the Company now refers to this product as CLBS16. CLBS16 is not the same product as and is not interchangeable with the Company’s CLBS14 treatment for no option refractory disabling angina.